The Lab Log
Curious about what’s inspiring us lately? Interested in knowing about what we’ve been researching at MEAL? We’re excited you’re interested in learning more.
Our lab log will keep you in the loop.
Overcoming Barriers in Eating Disorder Care
Hot off the press: our recently-published article in Applied Physiology, Nutrition, and Metabolism! This paper highlights the importance of understanding how systemic factors such as racism, weight stigma, and COVID-19 affect the assessment and treatment of eating disorders, and proposed strategies for addressing these inequities. We provide actionable recommendations for clinicians working with individuals with eating disorders; professional development, cultural competence, and equitable assessment and treatment practices are discussed.
The questions eating disorder experts have about weight loss medication
“We noticed clinically that we were getting more and more people into our clinical services that had been started on GLP-1 agonists and had experienced new onset or worsening eating disorder symptoms” – MEAL Co-Director, Dr. Aaron Keshen, was interviewed by CNN about the impact of weight loss medications on eating disorders.
Nutritional considerations for gender-diverse people: A qualitative mini review
This article summarizes qualitative literature on nutritional considerations for gender-diverse people. We discuss the need for increased trans literacy among clinicians, the creation of safe spaces for gender-diverse people with eating disorders, and the importance of dual competencies in eating disorders treatment and gender-affirming care. Read it in Frontiers in Nutrition!
Health service use among clients with eating disorders in New Brunswick
By examining administrative health data, we hope to gauge how often eating disorders appear in NB health records, the populations who access care for eating disorders, and the costs of seeking care. Hopefully, this information will inform efforts to build treatment capacity in NB!
Use of glucagon-like peptide-1 receptor agonists in eating disorder populations
Despite glucagon-like peptide-1 receptor agonists (GLP-1As; e.g., semaglutide) increasingly being the topic of clinical and public discourse, little is known about their potential impact on ED symptoms. Read more about it in our article in IJED!